Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6241572 | 0.87 | F10 (0.70) | F10LMNAHPGDTSHRF2 | |
| SCHEMBL6240965 | 0.87 | F10 (0.56) | F10LMNAHPGDTSHRNPC1 | |
| SCHEMBL6269594 | 0.82 | F10 (0.61) | F10LMNAHPGDTSHRF2 | |
| SCHEMBL6240513 | 0.82 | F10 (0.57) | F10LMNAHPGDTSHRF2 | |
| SCHEMBL6243572 | 0.80 | F10 (0.57) | F10F2NPC1 | |
| SCHEMBL6940357 | 0.79 | F10 (0.69) | F10F2NPC1MAPTFPR2 | |
| SCHEMBL6240173 | 0.78 | F10 (0.54) | F10F2 | |
| SCHEMBL8265326 | 0.78 | F10 (0.65) | F10 | |
| SCHEMBL6244121 | 0.76 | F10 (0.56) | F10LMNAHPGDTSHRMAPT | |
| SCHEMBL3833666 | 0.76 | F10 (0.60) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167131-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | PFIZER INC. | 2004-08-26 | — | — | US | claimed |
| EP-1539686-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040167131-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | PFIZER INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004024679-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167131-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | TFPI, SERPINC1, F11 | F10 13/4885LMNA 1099/4885HPGD 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.